Investor
Relations
A+ / A-

Raporty

1/2014 A significant contract with the National Health Fund

The Management Board of Centrum Medyczne ENEL-MED S.A. hereby announces that on 14 January 2014, the company received a signed amendment to its contract with the National Health Fund (Wielkopolska Voivodeship Branch of the National Health Fund, Poznań). The amendment sets out the terms and conditions of funding outpatient specialist medical services: cost-consuming diagnostic testing services in 2014. Following the amendment, the value of the contracts entered into between the company and the National Health Fund since the publication of current report 8/2013 on 05 February 2013 is PLN 4,702,354 net, exceeding 10% of the company’s equity.
The biggest contract between the company and the National Health Fund during the above period was an amendment to the company’s contract with the Lublin Voivodeship Branch of the National Health Fund, dated 21 November 2013.
The subject matter of the amendment is the provision of CT and MRI diagnostic testing services at the company’s laboratory in Lublin. The amendment, which is an extension to the company’s long-term contract for the period from 01 January 2011 to 31 December 2013 was signed for another twelve-month period (i.e. from 01 January 2014 to 31 December 2014) and its maximum value is PLN 1,629,450.00 net.
Under the amendment, the company is required to pay liquidated damages in the following cases:
  1. In the event of the company’s failure to perform in appropriate performance of the contract for reasons for which the company is liable, the Fund Branch may require the company to pay liquidated damages.
  2. If the company issues prescriptions to non-eligible persons and/or when it is unreasonable, the Fund Branch may require the company to pay liquidated damages equal to the amount of medication prices unduly reimbursed to the company against the prescriptions dispensed, plus statutory interest from the date of payment of the reimbursed amount.
  3. If the company issues prescriptions for orthopaedic medical devices and/or medical aids funded fully or partially by the National Health Fund to non-eligible persons and/or when it is unreasonable, the Fund Branch may require the company to pay liquidated damages equal to the amount unduly reimbursed to the company, plus statutory interest from the date of payment of the reimbursed amount.